menu

Spinal Muscular Atrophy Treatment Market

Schedule Call

Spinal Muscular Atrophy Treatment Market

Spinal Muscular Atrophy Treatment Market by Type (Type I, Type II, Others), by Drug Type (Onasemnogen Abeparvovec, Nusinersen), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2022-2030

GR - 477484 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: November 09, 2022

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Spinal Muscular Atrophy Treatment Market Scope

Report Attribute

Details

Market size value in 2021

US$ 1.2 billion

Revenue forecast in 2030

US$ 3.41 billion

Growth Rate

CAGR of 12.3% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Segments covered

type, drug type, distribution, and region.

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

The global spinal muscular atrophy treatment market was pegged at US$ 1.2 billion in 2021 and is expected to register a revenue CAGR of 12.3% during the forecast period of 2022 to 2030.

Market Fundamentals                                                                                          

Spinal muscular atrophy is a genetic disorder that affects the peripheral neurological system, the central nervous system, and the movement of voluntary muscles. It predominantly affects the spinal cord and weakens  voluntary muscles and atrophy. Thus, the loss of motor neurons results in spinal muscular atrophy, which causes a gradual loss of muscle control, movement, and strength.

[79834753]

Market Dynamics

The global spinal muscular atrophy (SMA) treatment market is an emerging industry and is expected to depict noticeable revenue growth during the forecast period. The growth of this revenue growth of this market can be attributed to the growing cases of spinal muscular atrophy and rising awareness about this rare disease and its available treatments. Additionally, a strong product pipeline, growing strategic collaborations/acquisitions, rising R&D activities, and technological advancements are expected to contribute to the market revenue growth. Moreover, the launch of novel therapies and products with enhanced results and the availability of reimbursement policies for such a rare disease is likely to boost the revenue growth of the global spinal muscular atrophy treatment market during the forecast period. However, the high cost of treatment and limited access to SMA treatment, especially in low-income countries, may hinder market revenue growth to some extent. 

Market Ecosystem

The global spinal muscular atrophy treatment market is analyzed from four perspectives: type, drug type, distribution, and region. 

Spinal Muscular Atrophy Treatment Market by Type

[2342344]

Based on type, the global spinal muscular atrophy treatment market is segmented into type I, type II, and others (type III and IV). The type I segment dominates the segment with the largest revenue share. Type I, also known as Wedding-Hoffmann disease, is the most common medical condition found in this SMA and highly occurs in infants or new-born, as this condition occurs due to faulty genes from the parent. This segment has the highest incidence among all the SMA, thus, it becomes the main cause of dominance of this segment. 

Type II segment SMA, also known as Dubowitz disease, has a considerable revenue share in the global spinal muscular atrophy treatment market, due to rising prevalence and increasing awareness among the population.

Spinal Muscular Atrophy Treatment Market by Drug Type

Based on the drug type, the global spinal muscular atrophy treatment market is segmented into onasemnogene abeparvovec and nusinersen. 

Nusinersen leads the segment with the largest revenue share in the market. This growth can be attributed to a better effect on the people suffering from SMA. This drug improves the quality of life by reducing the impact of SMA on the patient’s body and helps raise the SMN (spinal motor neuron) protein for normalizing the functionality of muscles and nerves. Furthermore, nusinersen has shown efficient clinical results in the clinical trial by prolonging the survival rate in children aged 2 years. Thus, these factors are encouraging the revenue growth of this segment. 

Theonasemnogen abeparvovec segment revenue is also growing at a good pace due to the rising adoption for treating SMA, thereby contributing to the revenue growth of the spinal muscular atrophy treatment market globally. 

Spinal Muscular Atrophy Treatment Market by Distribution Channel

Based on the distribution channel, the spinal muscular atrophy treatment market is segmented into hospital pharmacies and retail pharmacies. 

Hospital pharmacies dominate the global spinal muscular atrophy treatment market revenue due to the high patient volume and easy access to specialized care. Additionally, the fact that only highly trained, and skilled physicians administer the drugs used for treating such rare medical conditions is supporting the revenue growth of this segment.  

The retail pharmacies segment has a low contribution in terms of revenue.

Spinal Muscular Atrophy Treatment Market by Region

Based on the region, the global spinal muscular atrophy treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global spinal muscular atrophy treatment market with the largest revenue share. The rapid adoption of enhanced diagnostic and treatment technologies, availability of developed healthcare infrastructure with significant healthcare expenditures, and a strong base of market players contribute to the dominance of the spinal muscular atrophy treatment market in this region. Additionally, increased R&D activities, growth in strategic collaborations/partnerships, and availability of enhanced reimbursement policies for such rare diseases further contribute to the market revenue growth in this region. 

On the other hand, Asia Pacific is proliferating due to the developing healthcare infrastructure, rising healthcare expenditure, and increasing R&D activities. Moreover, improving medical tourism, increasing adoption of advanced technologies/therapies, and improving reimbursement policies are driving market revenue growth in this region.

Competitive Landscape

The prominent players operating in the global spinal muscular atrophy treatment market are:      

  • Astellas Pharma Inc.
  • Novartis AG
  • Biogen Inc.
  • Genentech Inc. (F. Hoffmann-La Roche Ltd.)
  • Genzyme Corporation
  • Ionis Pharmaceuticals Inc.
  • AstraZeneca Plc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Chugai Pharmaceutical Co. Ltd. (F. Hoffmann-La Roche Ltd.)
  • Cytokinetics Inc.
  • Catalyst Pharmaceuticals Inc.

Strategic Developments

  • In May 2021, Biogen and Ginkgo Bioworks announced a gene therapy collaboration. This collaboration aimed to develop a novel drug using recombinant adeno-associated virus (AAV)-based vectors for treating some neurological and neuromuscular diseases. 

Frequently Asked Questions About This Report

Asia Pacific is expected to be the fastest revenue generating regional market for spinal muscular atrophy treatment.

The estimated market size of the spinal muscular atrophy treatment market in 2030 is expected to be US$ 3.41 billion.

The global spinal muscular atrophy treatment market is expected to register a revenue CAGR of 12.3% during the forecast period.

The high cost of treatment and limited access to SMA treatment, especially in economically low countries, may hinder market revenue growth.

Astellas Pharma Inc., Novartis AG, Biogen Inc., Genentech Inc. (F. Hoffmann-La Roche Ltd.), and Genzyme Corporation are the top 5 players in the global spinal muscular atrophy treatment market.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trend (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021)
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
  5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY TYPE
    1. Type I 
    2. Type II 
    3. Others (Type III and Type IV)
  6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY DRUG TYPE
    1. Onasemnogen Abeparvovec
    2. Nusinersen
  7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies
  8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY REGION
    1. North America Spinal Muscular Atrophy Treatment Market
      1. North America Spinal Muscular Atrophy Treatment Market, by Type 
      2. North America Spinal Muscular Atrophy Treatment Market, by Drug Type 
      3. North America Spinal Muscular Atrophy Treatment Market, by Distribution Channel
      4. North America Spinal Muscular Atrophy Treatment Market, by Country
        1. U.S.
          1. U.S. Spinal Muscular Atrophy Treatment Market, by Type 
          2. U.S. Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. U.S. Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        2. Canada
          1. Canada Spinal Muscular Atrophy Treatment Market, by Type 
          2. Canada Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Canada Spinal Muscular Atrophy Treatment Market, by Distribution Channel
    2. Europe Spinal Muscular Atrophy Treatment Market
      1. Europe Spinal Muscular Atrophy Treatment Market, by Type 
      2. Europe Spinal Muscular Atrophy Treatment Market, by Drug Type 
      3. Europe Spinal Muscular Atrophy Treatment Market, by Distribution Channel
      4. Europe Spinal Muscular Atrophy Treatment Market, by Country/Region
        1. Germany
          1. Germany Spinal Muscular Atrophy Treatment Market, by Type 
          2. Germany Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Germany Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        2. U.K.
          1. U.K. Spinal Muscular Atrophy Treatment Market, by Type 
          2. U.K. Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. U.K. Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        3. France
          1. France Spinal Muscular Atrophy Treatment Market, by Type 
          2. France Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. France Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        4. Spain
          1. Spain Spinal Muscular Atrophy Treatment Market, by Type 
          2. Spain Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Spain Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        5. Italy
          1. Italy Spinal Muscular Atrophy Treatment Market, by Type 
          2. Italy Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Italy Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        6. Rest of Europe
          1. Rest of Europe Spinal Muscular Atrophy Treatment Market, by Type 
          2. Rest of Europe Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Rest of Europe Spinal Muscular Atrophy Treatment Market, by Distribution Channel
    3. Asia Pacific Spinal Muscular Atrophy Treatment Market
      1. Asia Pacific Spinal Muscular Atrophy Treatment Market, by Type 
      2. Asia Pacific Spinal Muscular Atrophy Treatment Market, by Drug Type 
      3. Asia Pacific Spinal Muscular Atrophy Treatment Market, by Distribution Channel
      4. Asia Pacific Spinal Muscular Atrophy Treatment Market, by Country/Region
        1. China
          1. China Spinal Muscular Atrophy Treatment Market, by Type 
          2. China Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. China Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        2. Japan
          1. Japan Spinal Muscular Atrophy Treatment Market, by Type 
          2. Japan Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Japan Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        3. India
          1. India Spinal Muscular Atrophy Treatment Market, by Type 
          2. India Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. India Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        4. South Korea
          1. South Korea Spinal Muscular Atrophy Treatment Market, by Type 
          2. South Korea Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. South Korea Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        5. Australia
          1. Australia Spinal Muscular Atrophy Treatment Market, by Type 
          2. Australia Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Australia Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, by Type 
          2. Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, by Distribution Channel
    4. Rest of the World Spinal Muscular Atrophy Treatment Market
      1. Rest of the World Spinal Muscular Atrophy Treatment Market, by Type 
      2. Rest of the World Spinal Muscular Atrophy Treatment Market, by Drug Type 
      3. Rest of the World Spinal Muscular Atrophy Treatment Market, by Distribution Channel
      4. Rest of the World Spinal Muscular Atrophy Treatment Market, by Region
        1. Latin America
          1. Latin America Spinal Muscular Atrophy Treatment Market, by Type 
          2. Latin America Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Latin America Spinal Muscular Atrophy Treatment Market, by Distribution Channel
        2. Middle East & Africa
          1. Middle America & Africa Spinal Muscular Atrophy Treatment Market, by Type 
          2. Middle America & Africa Spinal Muscular Atrophy Treatment Market, by Drug Type 
          3. Middle America & Africa Spinal Muscular Atrophy Treatment Market, by Distribution Channel
  9. COMPANY PROFILES 
    1. Astellas Pharma Inc.
      1. Business Snapshot 
      2. Drug Type Offered
      3. Financial Details
      4. Strategic Development
    2. Novartis AG
    3. Biogen Inc.
    4. Genentech Inc. (F. Hoffmann-La Roche Ltd.)
    5. Genzyme Corporation
    6. Ionis Pharmaceuticals Inc.
    7. AstraZeneca Plc.
    8. Pfizer Inc.
    9. Takeda Pharmaceutical Company Limited
    10. Chugai Pharmaceutical Co. Ltd. (F. Hoffmann-La Roche Ltd.)
    11. Cytokinetics Inc.
    12. Catalyst Pharmaceuticals Inc.

*Insights on financial performance are subject to the availability of information in the public domain


Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Spinal Muscular Atrophy Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Spinal Muscular Atrophy Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports